The determinants of R&D smoothing with asset sales: Evidence from R&D-intensive firms in China

被引:18
|
作者
Liu, Duan [1 ]
Li, Zhiyuan [1 ]
He, Hongbo [1 ]
Hou, Wenxuan [2 ]
机构
[1] Hunan Univ, Sch Business, Changsha, Peoples R China
[2] Univ Edinburgh, Sch Business, Edinburgh, Midlothian, Scotland
基金
中国国家自然科学基金;
关键词
R&D financing; Asset sale; Innovation efficiency; Financial constraint; FINANCIAL CONSTRAINTS EVIDENCE; CASH FLOW SENSITIVITY; INNOVATION EVIDENCE; DEVELOPMENT INVESTMENTS; CAPITAL ACCUMULATION; RELATIVE EFFICIENCY; TARGET FIRMS; ACQUISITIONS; UNCERTAINTY; PERFORMANCE;
D O I
10.1016/j.iref.2021.03.013
中图分类号
F8 [财政、金融];
学科分类号
0202 ;
摘要
Research and development (R&D)-intensive firms have strong incentives to maintain a smooth path for their R&D investments; otherwise, they will incur high adjustment costs. Examining data covering 2009 to 2016, we find that Chinese R&D-intensive firms, especially those with high innovation efficiency, tend to sell operating and financial assets to protect their value-enhancing R&D investments. However, financial constraints have adverse impacts on R&D smoothing with asset sales unless the firms have high innovation efficiency. The results suggest that innovation efficiency offers R&D-intensive firms, even financially constrained ones, a strong motivation to covert asset sales proceeds into R&D inputs, as the proceeds from asset sales provide a less-costly substitute for external financing. Given the importance of R&D for economic growth and the limited external financing opportunities in emerging capital markets like China, our findings reveal new insights regarding R&D financing.
引用
收藏
页码:76 / 93
页数:18
相关论文
共 50 条
  • [41] Does R&D cooperation with competitors cause firms to invest in R&D more intensively? evidence from Korean manufacturing firms
    BeomJu Park
    Chang-Yang Lee
    The Journal of Technology Transfer, 2023, 48 : 1045 - 1076
  • [42] The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan
    Jörg C. Mahlich
    Thomas Roediger-Schluga
    Review of Industrial Organization, 2006, 28 : 145 - 164
  • [43] The determinants of pharmaceutical R&D expenditures: Evidence from Japan
    Mahlich, JC
    Roediger-Schluga, T
    REVIEW OF INDUSTRIAL ORGANIZATION, 2006, 28 (02) : 145 - 164
  • [44] Are foreign-controlled manufacturing firms less R&D-intensive than canadian controlled firms?
    Tang, JM
    Rao, S
    CANADIAN PUBLIC POLICY-ANALYSE DE POLITIQUES, 2003, 29 (01): : 111 - 117
  • [45] Financial Asset Allocations and R&D Activities: Evidence from China's Listed Companies
    Liu, Guanchun
    Zhang, Jun
    Wu, Huihang
    Peng, Yuchao
    EMERGING MARKETS FINANCE AND TRADE, 2019, 55 (03) : 531 - 544
  • [46] R&D expenditure and managerial ownership: evidence from firms of high-vs-low R&D intensity
    Hassanein, Ahmed
    Al-Khasawneh, Jamal Ali
    Elzahar, Hany
    JOURNAL OF FINANCIAL REPORTING AND ACCOUNTING, 2023, 21 (03) : 654 - 672
  • [47] Change in sales, managerial overconfidence and persistence of firm R&D investment: evidence from China
    Wang, Zongjun
    Huang, Jinrong
    Jiang, Zhenyu
    ECONOMICS OF INNOVATION AND NEW TECHNOLOGY, 2022, 31 (08) : 711 - 728
  • [48] Are R&D-Intensive firms also corporate social responsibility specialists? A multicountry study
    Fu, Limin
    Boehe, Dirk
    Orlitzky, Marc
    RESEARCH POLICY, 2020, 49 (08)
  • [49] Productivity and R&D sources: evidence for Catalan firms
    Segarra, Agusti
    Teruel, Mercedes
    ECONOMICS OF INNOVATION AND NEW TECHNOLOGY, 2011, 20 (08) : 727 - 748
  • [50] On the R&D/marketing interface in knowledge intensive entrepreneurial firms
    Boles, James
    Link, Albert N.
    INTERNATIONAL ENTREPRENEURSHIP AND MANAGEMENT JOURNAL, 2017, 13 (03) : 943 - 952